U.K. Bars Puberty Blockers for Minors

The NHS announced the decision after a years-long study found no significant change in the mental health of children treated for gender dysphoria


John Stonestreet

Jared Hayden

Recently, the U.K.’s National Health Service (NHS) announced a new clinical policy barring the prescription of puberty-blocking drugs for minors. The decision came after a years-long public debate around transgender “care,” first started by a surge of referrals to the U.K.’s Tavistock gender clinic. After claims of malpractice, the NHS commissioned an independent review of the national clinic. 

The review found “no statistically significant difference in gender dysphoria, mental health, body image and psychosocial functioning in children and adolescents treated with [puberty blockers].” Review of additional data led the NHS to conclude “that there is not enough evidence to support the safety or clinical effectiveness of [puberty blockers] to make the treatment routinely available at this time.” 

In fact, puberty blockers are neither safe nor reversible, something even the World Professional Association for Transgender Health, the leading transgender medical organization, has been caught admitting.  

Thank God that the U.K. government will protect kids. Hopefully, the U.S. will follow suit. 


  • Facebook Icon in Gold
  • Twitter Icon in Gold
  • LinkedIn Icon in Gold

Have a Follow-up Question?

Related Content